{"id":"NCT01181141","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","officialTitle":"A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-08","completion":"2010-02","firstPosted":"2010-08-13","resultsPosted":"2015-01-26","lastUpdate":"2019-03-05"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"DU-176b (edoxaban)","otherNames":[]},{"type":"DRUG","name":"Enoxaparin sodium 20mg","otherNames":[]}],"arms":[{"label":"DU-176b","type":"EXPERIMENTAL"},{"label":"Enoxaparin sodium","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.","primaryOutcome":{"measure":"The Incidence of Major or Clinically Relevant Non-major Bleeding","timeFrame":"2 weeks","effectByArm":[{"arm":"DU-176b","deltaMin":3.4,"sd":null},{"arm":"Enoxaparin Sodium","deltaMin":6.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["24680549"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":59},"commonTop":["blood urine present","urinary tract infection","Aspartate aminotransferase increased","diarrhea","cystitis"]}}